Hims & Hers faces stock pressure after Novo Nordisk ends Wegovy access, citing compounding violations and marketing concerns.
Latest Ratings for HIMS
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Mar 2022 | Deutsche Bank | Initiates Coverage On | Hold | |
| Dec 2021 | Citigroup | Maintains | Buy | |
| Dec 2021 | Jefferies | Initiates Coverage On | Hold |
